News and Trends 11 Jan 2023 What the new year holds for clinical research Catherine Gregor is the chief clinical trial officer at Florence Healthcare. The company’s clinical trial software is used in more than 12,000 research sites in 45 countries for management of documents, data, and workflows. We asked Gregor about the clinical trial technology landscape in 2023. Why is remote clinical research connectivity so important? Remote connectivity […] January 11, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Silo Pharma looks into the 2023 psychedelics crystal ball Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […] January 11, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Biotech in Asia: looking forward to 2023 Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights into the state of the biopharma industry in 2023. Astellas is a Japanese headquartered pharmaceutical company active in more than 70 countries around the world. It promotes a ‘focus area approach’ designed to identify opportunities for the continuous creation of […] January 11, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Lifesciences and biotech in 2023 A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […] January 11, 2023 - 7 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Selecta and Astellas sign LOPD treatment agreement Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for late-onset Pompe disease (LOPD) in adults. Pompe […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 BD and CerTest Biotec receive emergency use authorization for mpox test BD (Becton, Dickinson and Company), and CerTest Biotec have announced emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX System users. “The […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Rani Therapeutics provides pipeline update Rani Therapeutics Holdings, Inc. has completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) with respect to RT-102, the RaniPill GO containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) for the potential treatment of osteoporosis, and provided a corporate update. Following feedback from the meeting with […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 ExeVir Bio secures funding for COVID program ExeVir Bio, a Belgian biotech company developing nanobody therapies for broad protection against infectious diseases, has secured a venture debt financing agreement of up to €25 million ($26.5 million) with the European Investment Bank (EIB). The EIB financing will help advance ExeVir Bio’s lead asset, XVR012, into clinical trials for COVID-19. ExeVir Bio’s COVID-19 development […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 BC Platforms to collaborate on Singapore population health study BC Platforms (BCP) has been selected to analyze and manage data collected from the Health for Life in Singapore (HELIOS) study, which forms part of the SG100K data set for Singapore’s National Precision Medicine program. The HELIOS study is a population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 ErVaccine raises €4.5M to start therapeutic cancer vaccine trial ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de l’Innovation (ADI) program. ErVaccine is a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, France, which develops next-generation […] January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email